The importance of atrial fibrillation burden and the origin of device-tailored anticoagulation

PACE - Pacing and Clinical Electrophysiology

Volumn 36, Issue 11, 2013, Pages 1319-1324

  Zimetbaum, Peter ^a   Ellis, Ethan R ^a   Waks, Jonathan W ^a   Passman, Rod S ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

atrial fibrillation; clinical trials; electrophysiology clinical

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; CARDIOVASCULAR CATHETER; CARDIOVERSION; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; REVIEW; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; CLINICAL TRIALS; ELECTROPHYSIOLOGY - CLINICAL;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CAUSALITY; COMORBIDITY; ELECTROCARDIOGRAPHY, AMBULATORY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INCIDENCE; MALE; PACEMAKER, ARTIFICIAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84886783653     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/pace.12275     Document Type: Review

References (14)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.
2. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
3. Hart RG, Halperin JL,. Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention. Ann Intern Med 1999; 131: 688-695.
4. Piccini JP, Singer DE,. Putting risk prediction in atrial fibrillation into perspective. Eur Heart J 2012; 33: 1431-1433.
5. Wolf PA, Abbott RS, Kannel WB,. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987; 147: 1561-1564.
6. Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH, Leong DP, et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: Impact of rate and rhythm. J Am Coll Cardiol 2013; 61: 852-860.
7. Weigner MJ, Caulfield TA, Danias PG, Silverman DI, Manning WJ,. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126: 615-620.
8. Capucci A, Santini M, Padeletti L, Gulizia M, Botto G, Boriani G, Ricci R, et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005; 46: 1913-1920.
9. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: The TRENDS study. Circ Arrhythm Electrophysiol 2009; 2: 474-480.
10. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, et al. Subclinical atrial fibrillation and the risk of stroke. N Eng J Med 2012; 366: 120-129.
11. Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Zolezzi F, Favale S, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: Crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009; 20: 241-248.
12. Ip J, Waldo AL, Lip GY, Rothwell PM, Martin DT, Bersohn MM, Choucair WK, et al. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: Rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study. Am Heart J 2009; 158: 364-370 e1.
13. Shanmugam N, Boerdlein A, Proff J, Ong P, Valencia O, Maier SK, Bauer WR, et al. Detection of atrial high-rate events by continuous home monitoring: Clinical significance in the heart failure-cardiac resynchronization therapy population. Europace 2012; 14: 230-237.
14. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: Report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003; 107: 1614-1619.